CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
AusperBio›
News
AusperBio logo

AusperBio

AusperBio develops antisense oligonucleotide and siRNA therapies aimed at a functional cure for chronic hepatitis B.

Foster City, CA, US🇺🇸
Founded
2019
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Latest News About AusperBio

AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

PR Newswire

AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

AusperBio closed a $120 million Series C led by a strategic investor with new backer RA Capital Management, funding the AHB-137 Phase 3...

Aug 27, 2026

AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171

PR Newswire

AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171

AusperBio dosed the first patient with AHB-171, its investigational HBV siRNA candidate and the first clinical asset from the Au-HALO...

Aug 3, 2026

AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B

PR Newswire

AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B

AusperBio completes enrollment in Phase III AUSHINE trial for AHB-137, its lead ASO for functional cure of CHB.

Dec 22, 2025

AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy

PR Newswire

AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy

AusperBio reported that AHB-137 monotherapy reached a 30% functional cure rate in HBeAg-negative chronic hepatitis B patients maintained on...

Dec 12, 2025

AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025

PR Newswire

AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025

Pooled 48-week results from the NCT06115993 and NCT06550128 Phase II studies, presented in a late-breaking poster at AASLD The Liver...

Nov 8, 2025

AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B

PR Newswire

AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B

AusperBio closed $63M Series B2 co-led by Qiming Venture Partners to advance AHB-137 pivotal trial and Med-Oligo platform for CHB...

Sep 21, 2025